MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • June 2016

AiVita Biomedical Receives FDA Approval for Phase II Ovarian Cancer Treatment

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Chief Medical Officer Dr. Robert Dillman to Deliver Keynote at World Immunotherapy Congress
  • AIVITA Biomedical CEO Dr. Hans Keirstead Joins Human Immunome Project Board of Directors
  • TAE Life Sciences and AIVITA Biomedical Announce Strategic Partnership to Advance Development of Target Boron Drugs for Glioblastoma
  • AIVITA Biomedical Chief Medical Officer Dr. Robert O. Dillman to Deliver Keynote and Chair Cancer Immunotherapy Track at World Vaccine and Immunotherapy Congress
  • AIVITA Biomedical CMO Dr. Robert Dillman to Deliver Keynote at Vaccines Summit 2022

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2020 | AIVITA Biomedical, Inc.